Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6187432 | 1.00 | CES1 (0.50) | CES1CES2AKR1B1ALDH1A1TSHR | |
| SCHEMBL17708570 | 0.78 | CES1 (0.55) | CES1CES2AKR1B1ALDH1A1TSHR | |
| SCHEMBL2241627 | 0.78 | CES1 (0.55) | CES1CES2AKR1B1ALDH1A1TSHR | |
| SCHEMBL822099 | 0.78 | CES1 (0.55) | CES1CES2AKR1B1ALDH1A1TSHR | |
| SCHEMBL12095508 | 0.78 | CES1 (0.55) | CES1CES2AKR1B1ALDH1A1TSHR | |
| SCHEMBL31208444 | 0.77 | CES1 (0.67) | CES1CES2AKR1B1ALDH1A1TSHR | |
| SCHEMBL5610463 | 0.77 | CES1 (0.54) | CES1CES2AKR1B1ALDH1A1TSHR | |
| SCHEMBL1333665 | 0.76 | CES1 (0.52) | CES1CES2AKR1B1ALDH1A1TSHR | |
| Ammonia Solution, Strong SCHEMBL574785 | 0.76 | CES1 (0.52) | CES1CES2AKR1B1ALDH1A1TSHR | |
| SCHEMBL3855307 | 0.76 | CES1 (0.52) | CES1CES2AKR1B1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109232422-B | Preparation method of celecoxib | 烟台万润药业有限公司 | 2020-07-07 | — | — | CN | claimed |
| CN-109232422-A | A kind of preparation method of celecoxib | 烟台万润药业有限公司 | 2019-01-18 | — | — | CN | claimed |
| CN-111484453-B | Synthesis method of celecoxib | 福建海西新药创制股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-111484453-A | Synthesis method of celecoxib | 福建海西新药创制有限公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-109232422-B | Preparation method of celecoxib | 烟台万润药业有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-109232422-B | Preparation method of celecoxib | 烟台万润药业有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-23 | — | — | US | disclosed |
| CN-109232422-A | A kind of preparation method of celecoxib | 烟台万润药业有限公司 | 2019-01-18 | — | — | CN | disclosed |
| CN-109232422-A | A kind of preparation method of celecoxib | 烟台万润药业有限公司 | 2019-01-18 | — | — | CN | disclosed |
| WO-2013122364-A2 | COMPOUND FOR ORGANIC ELECTRICAL ELEMENT, ORGANIC ELECTRICAL ELEMENT COMPRISING SAME, AND ELECTRONIC DEVICE THEREWITH | 덕산하이메탈(주) (KR) | 2013-08-22 | — | — | WO | disclosed |
| US-20110190137-A1 | METHOD TO INHIBIT ETHYLENE RESPONSES IN PLANTS | JACOBSON RICHARD MARTIN | 2011-08-04 | — | — | US | disclosed |
| US-7296576-B2 | Polymers for enhanced solubility of nanomaterials, compositions and methods therefor | ZYVEX PERFORMANCE MATERIALS, LLC (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060041104-A1 | Polymers for enhanced solubility of nanomaterials, compositions and methods therefor | ZYVEX CORPORATION (US) | 2006-02-23 | — | — | US | disclosed |
| EP-1409440-A4 | A METHOD TO INHIBIT ETHYLENE RESPONSES IN PLANTS | ROHM & HAAS (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050065033-A1 | Method to inhibit ethylene responses in plants | JACOBSON RICHARD MARTIN (US) | 2005-03-24 | — | — | US | disclosed |
| EP-1409440-A1 | A METHOD TO INHIBIT ETHYLENE RESPONSES IN PLANTS | ROHM AND HAAS COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002068367-A1 | A METHOD TO INHIBIT ETHYLENE RESPONSES IN PLANTS | ROHM AND HAAS COMPANY (US) | 2002-09-06 | — | — | WO | disclosed |
| US-4594467-A | DEHYDROBROMINATING ALPH-BROMO-3,5-DICHLORO CUMENE WITH ALKALI METAL HYDROXIDE IN PRESENCE OF PHASE TRANSFER CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 1986-06-10 | — | — | US | disclosed |
| US-4446076-A | Method of preparing 1,2-dibromo-2-cyano-(substituted)-alkane antimicrobial compounds | MERCK & CO., INC. (US) | 1984-05-01 | — | — | US | disclosed |
| US-4366170-A | 1,2-Dibromo-2-cyano-2-(aryl)ethane(propane) antimicrobial compounds | MERCK & CO., INC. (US) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065033-A1 | Method to inhibit ethylene responses in plants | ERN1, CTH, CBS | CES1 820/4885CES2 191/4885AKR1B1 2087/4885 |
| US-20110190137-A1 | METHOD TO INHIBIT ETHYLENE RESPONSES IN PLANTS | ERN1, CTH, CBR3 | CES1 721/4885CES2 154/4885AKR1B1 2037/4885 |
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | YAP1, ICOSLG, SPIN3 | CES1 4488/4885CES2 4184/4885AKR1B1 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.